Gensignia appoints CEO at US subsidiary

Lee McCracken joins the company from Pathwork Diagnostics

Gensignia, a London-based privately held microRNA company, has appointed Lee McCracken as Chief Executive of its subsidiary, Gensignia Life Sciences, Inc.

McCracken will lead the San Diego-based company with the aim of advancing Gensignia’s 'Dx/Rx' business model in oncology, with an initial focus on launching the company’s molecular diagnostic test for early detection of lung cancer.

McCracken has more than 20 years’ experience in the pharmaceutical, biotechnology, diagnostics and venture capital industries. He was recently President and CEO of Pathwork Diagnostics. Pathwork developed and commercialised an FDA-approved molecular diagnostic for cancer and was sold to Response Genetics in 2013.

Previously, McCracken held senior roles at Prometheus Laboratories, Diversa, GenStar Therapeutics, CombiChem and Allergan. He began his career in venture capital at Union Venture before joining 3i Capital.

You may also like

Research & Development

OGT launches new SureSeq myeloid fusion panel drive myeloid cancer research

The assay enables users to integrate research techniques with a single, streamlined NGS process, expediting the process
Regulatory

Compact process thermostat for efficient temperature control in the lab

The Petite Fleur allows for laboratory reactor temperature control between -40 °C to +200 °C with a 480W refrigeration capacity
Research & Development

Lonza's AI-enabled small molecule development tool launches

The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Manufacturing

Miltenyi Biotec and MiLaboratories collaborate to advance next-generation therapies

Miltenyi Biotec will commercialise MiLaboratories' RNA kit technology for immune sequencing, facilitating advances in the field of personalised medicine
Research & Development

Abzena launches EpiScreen 2.0 to assist the development of complex biologics and bioconjugates

The updated platform delivers an advanced range of immune response measurements, while also providing information on mechanism-of-action and specificity
Research & Development

COVID-19 still a significant risk for the immunocompromised, study finds

AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
Research & Development

N4 Pharma and SRI to target and treat previously unreachable human cells

The companies will collaborate to perform research to conjugate SRI’s MGS system to Nuvec to increase intracellular delivery to specific target cells.
Subscribe now